Search

Search Constraints

You searched for: Author/Creator Johanns, Jewel

Search Results

2. Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction Trial: 689. (October 2019)

3. Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate ‐ Severe Crohn's Disease Patients: Results from the IM‐UNITI Maintenance Study: 2016 ACG Presidential Poster Award: 663. (October 2016)

4. Endoscopic Healing in Induction and Maintenance with Ustekinumab in the Phase 3 UNITI Crohn's Disease Program: 2016 ACG Presidential Poster Award: 605. (October 2016)

5. Exposure‐Response to SC Ustekinumab In Moderate‐Severe Crohn's Disease: Results From the IM‐UNITI Maintenance Study: 660. (October 2017)

6. Fecal Lactoferrin (fLac) and Calprotectin (fCal) as Surrogate Markers of Mucosal Healing: Post‐hoc Analysis from the PURSUIT SC Induction Study: 1864. (October 2015)

7. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. (April 2023)

8. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. (3rd June 2019)

9. Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI: 842. (October 2019)

10. Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT‐SC Maintenance Study Extension Through 1 Year. Issue 4 (April 2016)